SCHEMBL7223142

SCHEMBL7223142

C=C[C@H](CC(=O)CC(=O)O)c1cccc(F)c1

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
HDAC4 P56524 1/20 0.43
HDAC7 Q8WUI4 1/20 0.43
HDAC5 Q9UQL6 1/20 0.43
CNR2 P34972 1/20 0.43
CTSA P10619 2/20 0.40
CES2 O00748 1/20 0.39
CES1 P23141 1/20 0.39
POLB P06746 1/20 0.38
MAPT P10636 1/20 0.38
MAPK1 P28482 1/20 0.38
CYP26A1 O43174 1/20 0.38
PGR P06401 1/20 0.37
AR P10275 1/20 0.37
SLC6A9 P48067 1/20 0.37
SLC6A5 Q9Y345 1/20 0.37
MTOR P42345 1/20 0.36
KDM4E B2RXH2 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7216851 0.88 HDAC4 (0.44) HDAC4HDAC7HDAC5CNR2CTSA
SCHEMBL7218571 0.76 CNR2 (0.36) HDAC4HDAC7HDAC5CNR2CTSA
SCHEMBL7218575 0.73 HDAC4 (0.36) HDAC4HDAC7HDAC5CNR2CTSA
SCHEMBL16962476 0.72 AOC3 (0.40) HDAC4HDAC7HDAC5CNR2CES2
SCHEMBL5149908 0.72 HDAC4 (0.51) HDAC4HDAC7HDAC5CNR2CTSA
SCHEMBL8539961 0.72 CYP2C19 (0.40) POLBMAPTKDM4E
SCHEMBL3659315 0.72 FFAR1 (0.46) KDM4E
SCHEMBL8217036 0.72 HPGD (0.41) POLB
SCHEMBL3657744 0.72 FFAR1 (0.46) KDM4E
SCHEMBL2498890 0.72 FFAR1 (0.46) KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6593346-B2 Substituted 3-(piperidin-1-ylmethyl)cyclopentylamines, useful as modulators of the chemokine receptors CCR-5 and/or CC R-3. MERCK & CO. INC. 2003-07-15 US disclosed
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity MERCK SHARP & DOHME CORP. 2002-08-29 US disclosed
US-6358979-B1 FOR THERAPY AND PROPHYLAXIS OF ASTHMA, ALLERGIC RHINITIS, DERMATITIS, CONJUNCTIVITIS, ATHEROSCLEROSIS OR RHEUMATOID ARTHRITIS, INFECTION BY HIV, TREATING INFECTION BY HIV, DELAYING OF THE ONSET OF AIDS MERCK & CO., INC. 2002-03-19 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020120146-A1 N-cyclopentyl modulators of chemokine receptor activity CCR1, CCR3, CCR5 HDAC4 2224/4885HDAC7 1542/4885HDAC5 1038/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.